GeneralConnection.com ➔ Dictionary
Dictionary Search

achondroplasia

Synonyms

Noun

1. achondroplasty

2. osteosclerosis congenita, chondrodystrophy, genetic disease, genetic disorder, genetic abnormality, genetic defect, congenital disease, inherited disease, inherited disorder, hereditary disease, hereditary condition

Usage
BioMarin, Ascendis slide as BridgeBio shakes up achondroplasia landscape - MSN
Abbisko Therapeutics' FGFR2/3 inhibitor ABSK061 receives FDA IND clearance for achondroplasia in children - Select Science
Excess FGFR3 signaling in achondroplasia disrupts turnover of resting zone chondrocytes via CREB signaling - Nature
BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial - TipRanks
Homozygous Achondroplasia With Long-Term Survival: Growth Patterns, Medical Interventions, and Practice Implications - Wiley Online Library
Finding the right team for achondroplasia: Jeremy’s story - Boston Children's Answers
Once-Weekly Navepegritide Safe and Efficacious for Achondroplasia, With Carlos Bacino, MD - HCPLive
COACH trial: hGH accelerates CNP benefits in achondroplasia - The Clinical Trial Vanguard
Oral infigratinib boosts growth velocity in achondroplasia study - 2 Minute Medicine
Achondroplasia - The Lancet
Oral medication boosts annualized height velocity for children with achondroplasia - Healio
UK consensus guidelines for multidisciplinary care of children and young people with achondroplasia: a modified Delphi process - Archives of Disease in Childhood
New treatment gives hope to children with achondroplasia - Loma Linda University
Jake Birecki Makes Space for Passion, Purpose and Play - BioMarin Pharmaceutical
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug - BioSpace
United States Achondroplasia Market 2026 | Growth Drivers, Key Players & Investment Opportunities - openPR.com
FDA approves dwarfism drug - Nature
‘Highly Impressive’ Data Propels BridgeBio’s Achondroplasia Drug Forward - BioSpace
Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial - HCPLive
Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel - Fierce Pharma
How Turner and Achondroplasia Data plus Board Addition Could Shape Ascendis Pharma’s (ASND) Pipeline Strategy - Yahoo Finance
Oral Infigratinib Meets Annualized Height Velocity Endpoint in Phase 3 Achondroplasia Trial - HCPLive
Once-weekly navepegritide plus lonapegsomatropin demonstrates growth in children with achondroplasia - Contemporary Pediatrics
Oral infigratinib linked to improved growth and proportionality in achondroplasia - Contemporary Pediatrics
FDA pushes back decision on Ascendis' achondroplasia drug to February - FirstWord Pharma
New mouse model uncovers achondroplasia's cellular growth plate dysregulation - News-Medical
The latest on navepegritide for children with achondroplasia, with Carlos Bacino, MD - Contemporary Pediatrics
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
BridgeBio drug for genetic cause of dwarfism succeeds in key study - statnews.com
Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children - Yahoo Finance
First-of-its-kind trial boosts growth in children with rare disorders - Children's National Hospital
Once-weekly agent boosts annualized growth velocity for children with achondroplasia - Healio
Navepegritide demonstrates growth velocity, skeletal alignment in children with achondroplasia - Contemporary Pediatrics
FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older - HCPLive
COACH Trial Confirms Durable Benefits in Achondroplasia - The Clinical Trial Vanguard
Once-Weekly Treatment Approved for Achondroplasia in Kids - MedPage Today
Ascendis reports arm span, spinal improvements in achondroplasia trial - Investing.com
BridgeBio preps approval push after dwarfism drug increases children's height in phase 3 - Fierce Biotech
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia - PR Newswire
Ascendis Pharma Receives FDA Approval for YUVIWEL®, First Once-Weekly Treatment for Achondroplasia in Children - Quiver Quantitative
Tyra Biosciences initiates paediatric study for achondroplasia treatment - Clinical Trials Arena
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
Drug Combo ‘Potentially Revolutionary’ for Achondroplasia - Medscape
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months - BioSpace
Novel Combination Improved Growth in Kids With Achondroplasia, Study Suggests - MedPage Today
New Two-Year Data from Pivotal ApproaCH Trial Showing - GlobeNewswire
Assessing Abbisko Cayman (SEHK:2256) Valuation After FDA Clears ABSK061 IND For Pediatric Achondroplasia - Yahoo Finance
How Investors May Respond To Ascendis Pharma (ASND) Achondroplasia Combo Data And YUVIWEL Launch - Sahm
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia - Yahoo Finance
FDA approves Ascendis’ once-weekly achondroplasia treatment - Investing.com
Camp Ellellbee Creates Space for Connection, Joy and Open Conversations About Skeletal Conditions - BioMarin Pharmaceutical
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - Yahoo Finance
FDA Okays Weekly Option in Achondroplasia - Conexiant
Inside pharma’s race to deliver new treatments for dwarfism - Pharma Voice
BridgeBio stock jumps after positive Phase 3 results for achondroplasia drug - Investing.com
Early VOXZOGO Data May Reshape BioMarin Growth Expectations In Achondroplasia - simplywall.st
Ascendis Submits Marketing Authorisation Application to the - GlobeNewswire
Here we grow: chondrocytes’ behavior reveals novel targets for bone growth disorders - Asia Research News |
Ascendis reports strong results for achondroplasia combination therapy - Investing.com
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share - Citeline News & Insights
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal - BioSpace
Ascendis wins FDA approval for achondroplasia drug, waits on EU action - Endpoints News
BioMarin reports growth data for achondroplasia drug VOXZOGO - Investing.com
US FDA clears four NMEs, including those for dermatitis, achondroplasia - BioWorld News
Ascendis Announces Extension of FDA Review Period for - GlobeNewswire
BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data - Investing.com
Ascendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia - TipRanks
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace
Weekly achondroplasia drug combo posts 9.4 cm arm span gain in 52 weeks - Stock Titan
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Yahoo Finance
FDA accepts navepegritide application to treat children with achondroplasia - Contemporary Pediatrics
Ribomic’s RBM-007 ready for phase III in achondroplasia - BioWorld News
Ascendis reports interim analysis outcomes from achondroplasia trial - Clinical Trials Arena
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
Can TransCon CNP Reshape Achondroplasia Treatment? FDA Decision Due Nov. 30 - RTTNews
Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld News
Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - Yahoo Finance
BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia - Yahoo Finance
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears - Yahoo Finance
BridgeBio Pharma Reports Positive Topline Results from PROPEL 3 Study of Oral Infigratinib in Children with Achondroplasia - Quiver Quantitative
FDA Approves Once-Weekly Yuviwel® (Navepegritide) For Children With Achondroplasia Aged 2 Years And Older - TradingView
BridgeBio gains on phase 3 dwarfism data - pharmaphorum
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - Yahoo Finance
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop - MedPage Today
Biomarin Receives Health Canada Notice Of Compliance With Conditions For Voxzogo®, For Achondroplasia - TradingView
Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia - Contemporary Pediatrics
Ascendis scores FDA approval for weekly dwarfism drug - pharmaphorum
Doctor helps Colorado boy with dwarfism thrive at school - KUSA.com
BioMarin touts promising early result for potential Voxzogo successor - Fierce Pharma
BridgeBio data for dwarfism drug sets up showdown with BioMarin's Voxzogo - FirstWord Pharma
BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results - TipRanks
Small start, big gains: Loma Linda brings hope to a young patient - American Hospital Association
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - Bitget
BioMarin receives Health Canada Notice of Compliance with conditions for VOXZOGO®, for Achondroplasia - Newswire Canada
Once Weekly CNP Therapy Shows Promise In Advancing Achondroplasia Treatment - BioSpectrum Asia
Week 52 COACH trial top-line results confirm durable treatment benefits - The Pharma Letter
Foreign Language Equivalents
Foreign Language Equivalents of 'achondroplasia'
Language Equivalent   Language Equivalent
French achondroplasie    Spanish
Misspellings - Typos
achindroplasia,   achondrop;asia,   achondro[lasia,   achoondroplasia,   chondroplasia,   achondroplaisa,   achondroplsia,   achobdroplasia,   aachondroplasia,   acohndroplasia,   achonroplasia,   achondroplaia,   achondroplasai,   achondroplaaia,   achondropplasia,   achondroplassia,   achondorplasia,   achnodroplasia,   achondropasia,   achondrolpasia,   achondoplasia,   achonndroplasia,   achondrplasia,   acgondroplasia,   achndroplasia,   achondropalsia,   achondroplssia,   achonrdoplasia,   acondroplasia,   achondrpplasia,   achondroplasiaa,   achondrooplasia,   avhondroplasia,   achpndroplasia,   achondropllasia,   achondrroplasia,   achondroplasiia,   achondrolasia,   achondroplsaia,   acjondroplasia,   achondtoplasia,   achondrpolasia,   achondropkasia,   ahondroplasia,   achodnroplasia,   achondroplasi,   achondriplasia,   axhondroplasia,   ahcondroplasia,   achondropladia,   achonddroplasia,   achondroolasia,   achonfroplasia,   achondroplasis,   achondroplasa,   achondeoplasia,   achondroplasua,   achomdroplasia,   achondroplaasia,   achondroplasoa,   cahondroplasia,   achonsroplasia,   acchondroplasia,   schondroplasia,   achodroplasia,   achhondroplasia
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z